John Landry
Podiatrist · Arlington, TXNPI 1710936158
Payments from drug & device makers
Across 49 payments — averaging $92.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$2K
- Treace Medical Concepts, Inc.$1K
- Nevro Corp.$245
- Bioventus LLC$142
- Smith+Nephew$132
- Amgen$105
- plus $376 from 10 others
What the payments were for
- Travel & lodging$80318%
- Food & beverage$1,40131%
- Education$2,31551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 3 | $2,346 |
| Treace Medical Concepts, Inc. | 11 | $1,173 |
| Nevro Corp. | 3 | $245 |
| Bioventus LLC | 6 | $142 |
| Smith+Nephew | 4 | $132 |
| Amgen(2 entities) | 5 | $105 |
| Paratek Pharmaceuticals, Inc. | 3 | $57 |
| Pacira Pharmaceuticals Incorporated | 2 | $51 |
| Abbott | 2 | $48 |
| IBSA Pharma Inc. | 2 | $44 |
| Stryker | 1 | $40 |
| Solventum Corporation | 2 | $40 |
| Orthofix Medical, Inc. | 2 | $34 |
| Zimmer Biomet | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LAPIPLASTY SYSTEM 1$766
- Senza$210
- Lapiplasty System$127
How this compares
$4,519 in reported general payments places this provider in the 65th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 40 | $1,941 |
| Terbinafine Hcl | 207 | $1,925 |
| Gabapentin | 78 | $1,244 |
| Ammonium Lactate | 45 | $727 |
| Meloxicam | 83 | $481 |
| Allopurinol | 46 | $405 |
| Diclofenac Sodium | 11 | $269 |
| Pregabalin | 16 | $265 |
| Mupirocin | 31 | $257 |
| Doxycycline Hyclate | 37 | $227 |
| Methylprednisolone | 24 | $226 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $206 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $88 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Arlington
- Dharmesh BhaktaArlington$105K
- Brian CarpenterFort Worth$1.2M
- Gary LepowHouston$1M
- Travis MotleyFort Worth$888K
- Wayne HurstCedar Park$625K
- Calvin RushingSunnyvale$462K
- Lena LevineFort Worth$298K
- Robert TaylorFrisco$280K
- Alan GarrettFort Worth$236K
- Patrick BriggsWebster$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.